Search

Displaying results 1561 - 1570 of 4692 in total
  1. Drug

    Cyclandelate

    go.drugbank.com/drugs/DB04838
    ApprovedWithdrawn

    Cyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.

  2. Drug

    Zileuton

    go.drugbank.com/drugs/DB00744
    ApprovedWithdrawn

    The immediate release tablet of Zileuton has been withdrawn from the US market.

  3. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion

  4. Drug

    Norethisterone

    go.drugbank.com/drugs/DB00717
    ApprovedInvestigational

    [A10367] It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [norethynodrel] and [lynestrenol

  5. Drug

    Verapamil

    go.drugbank.com/drugs/DB00661
    ApprovedInvestigational

    [A188514] It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications … racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but

  6. Drug

    Emapalumab

    go.drugbank.com/drugs/DB14724
    ApprovedInvestigational

    Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018. … [L4840] As well, emapalumab was given the status of PRIME by the EMA.[L4845]

  7. Drug

    SPL23-2

    go.drugbank.com/drugs/DB17866
    Experimental

    SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of cystic fibrosis.[L46767]

  8. Drug

    Elexacaftor

    go.drugbank.com/drugs/DB15444
    ApprovedInvestigational

    [A187361] The triple combination product Trikafta<sup>TM</sup>, manufactured by Vertex Pharmaceuticals, is the first product approved for the treatment of CF in individuals who are either homo- _or_ heterozygous

  9. Drug

    Droxidopa

    go.drugbank.com/drugs/DB06262
    ApprovedInvestigational

    The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension.

  10. Drug

    Mineral oil

    go.drugbank.com/drugs/DB11057
    ApprovedInvestigationalVet approved

    During the modern refining process, aromatics are reduced by solvent extraction, catalytic hydrotreating, or hydrocracking. … Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined.

    Mixtures: Mizon Collagenic Aqua Volume Up Li P Essence Renewal